Replimune Group, Inc. (NASDAQ:REPL) Stock Has Average Price Target of $14.33

Shares of Replimune Group, Inc. (NASDAQ:REPL) have earned a consensus rating of “Moderate Buy” from the ten brokerages that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $14.33.

A number of equities analysts have recently commented on the company. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price for the company in a report on Friday, August 7th. JPMorgan Chase & Co. increased their price target on Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, August 26th. Leerink Partners raised their price target on Replimune Group from $19.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday, October 29th. Wall Street Zen raised shares of Replimune Group from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. Finally, Wolfe Research raised shares of Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th.

Replimune Group Stock Up 3.0%

Shares of NASDAQ:REPL opened at $22.26 on Friday. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -7.98 and a beta of 0.93. Replimune Group has a 12 month low of $1.50 and a 12 month high of $22.72. The company has a current ratio of 7.11, a quick ratio of 6.90 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $14.23 and a 200 day moving average price of $9.75.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.24. As a group, equities research analysts predict that Replimune Group will post -2.40 earnings per share for the current year.

Insider Transactions at Replimune Group

In related news, Director Kapil Dhingra sold 21,500 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $19.00, for a total transaction of $408,500.00. Following the transaction, the director directly owned 21,669 shares in the company, valued at approximately $411,711. This represents a 49.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Emily Hill sold 9,256 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $14.28, for a total transaction of $132,175.68. Following the completion of the sale, the chief financial officer directly owned 215,852 shares in the company, valued at $3,082,366.56. This trade represents a 4.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of REPL. BlackRock Inc. purchased a new stake in Replimune Group in the second quarter worth $99,171,000. Montanova Capital LLC increased its stake in Replimune Group by 4.0% in the 2nd quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock worth $48,595,000 after buying an additional 168,000 shares during the period. Opaleye Management Inc. purchased a new position in Replimune Group in the 2nd quarter worth about $15,332,000. Dimensional Fund Advisors LP lifted its holdings in Replimune Group by 1.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company’s stock valued at $8,719,000 after buying an additional 20,742 shares in the last quarter. Finally, EcoR1 Capital LLC bought a new stake in Replimune Group during the 1st quarter valued at about $7,650,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer.

The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.